{"id":1729,"date":"2019-04-08T10:52:27","date_gmt":"2019-04-08T14:52:27","guid":{"rendered":"https:\/\/web.uri.edu\/cehp\/?p=1729"},"modified":"2019-04-08T13:45:42","modified_gmt":"2019-04-08T17:45:42","slug":"transporters-test","status":"publish","type":"post","link":"https:\/\/web.uri.edu\/pharmce\/transporters-test\/","title":{"rendered":"Transporters Test"},"content":{"rendered":"

Transporters in Drug Discovery and Development<\/h1>

Driving Knowledge from Laboratory to Label<\/p><\/div><\/div>

<\/div>
Accessibility controls<\/div>
Pause motion<\/div>
Motion: On<\/span><\/div><\/div>
Play motion<\/div>
Motion: Off<\/span><\/div><\/div><\/div>
Increase text contrast<\/div>
Contrast: Standard<\/span><\/div><\/div>
Reset text contrast<\/div>
Contrast: High<\/span><\/div><\/div><\/div>
<\/div>
Apply site-wide<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n

August 5 & 6, 2019 8:00 am to 5:00 pm
\n<\/b>Avedisian Hall, 7 Greenhouse Road, Kingston, RI 02881<\/p>\n

Overview<\/h1><\/p>\n

Several factors led to the recent emphasis on the field of transporters and their impact on drug absorption and disposition. Pharmaceutical industry continues to have keen interest in optimizing the physicochemical space of NCEs and minimizing their Cytochrome P-450 (CYP)-mediated metabolic liability. This led to the increasing selection of compounds that are both hydrophilic and polar in nature. Such chemical space inherits low passive permeability and metabolic clearance characteristics, and more importantly have potential contribution of transporters to their disposition in man. This paradigm shift presents the research community with a more difficult chemical space for addressing drug absorption and predicting pharmacokinetics and tissue distribution. Appropriate understanding of transporters and in vitro and in silico tools that characterize their contribution to drug absorption, disposition and toxicity is key for the success of the pharmaceutical industry. Additionally, the US FDA, EMA and other regulatory agencies provided new guidance on approaches to assess the liabilities of transporter-mediated drug-drug interaction (DDI), efficacy and organ toxicity for new chemical entities (NCEs) with special emphasis on certain transporters with considerable knowledge in the clinic.<\/p>\n

Good course and speakers kept my attention. Materials were good, breaks at appropriate time. Good networking opportunities. Nice receptions and good food. Overall, very well organized. This course was highly recommended to me and I will highly recommended it to others. Excited to be back to work and retrospectively looking at compounds using ECCS classification.<\/blockquote>2017 Participant<\/cite><\/div><\/section><\/p>\n

Who should attend this course?<\/h3>\n

The interest in the field of transporters and their impact on drug absorption and disposition has been re-invigorated due to recent FDA and EMA guidance on approaches to assess transporter mediated DDI liabilities for NME. Therefore, this course is designed to serve a variety of scientific communities.<\/p>\n